Meeting
2021 Gastrointestinal Cancers Symposium
Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer.
Authors
Kensei Yamaguchi
Japanese Foundation for Cancer Research, Tokyo, Japan
Kensei Yamaguchi , Yoon-Koo Kang , Do-Youn Oh , Shunsuke Kondo , Sun Young Rha , Yasutoshi Kuboki , Manabu Morimoto , Hiroki Hara , Chia-Chi Lin , Yoshifumi Tachibana , Jianrui Hou , Mabrouk M. Elgadi , Shigehisa Kitano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Esophageal and Gastric Cancer
Track
Esophageal and Gastric Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03433898
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 212)
DOI
10.1200/JCO.2021.39.3_suppl.212
Abstract #
212
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors.
First Author: Yoon-Koo Kang
Poster
2021 ASCO Annual Meeting
Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.
First Author: Thorsten Oliver Goetze
Poster
2020 ASCO Virtual Scientific Program
Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.
First Author: Melissa Lynne Johnson
First Author: Igor Tsaur